Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239185 | 0.87 | GPR119 (0.42) | GPR119RORC | |
| SCHEMBL1006506 | 0.84 | GPR119 (0.47) | GPR119FPR2PROKR1KDM4ENPC1 | |
| SCHEMBL1008624 | 0.82 | GPR119 (0.47) | GPR119FPR2PROKR1KDM4ENPC1 | |
| SCHEMBL1004543 | 0.82 | GPR119 (0.45) | GPR119FPR2PROKR1KDM4ENPC1 | |
| SCHEMBL1006028 | 0.80 | GPR119 (0.46) | GPR119FPR2PROKR1KDM4ENPC1 | |
| SCHEMBL1005456 | 0.78 | GPR119 (0.45) | GPR119FPR2PROKR1KDM4ENPC1 | |
| SCHEMBL1005476 | 0.77 | GPR119 (0.46) | GPR119FPR2PROKR1KDM4ENPC1 | |
| SCHEMBL1006023 | 0.77 | GPR119 (0.47) | GPR119FPR2PROKR1 | |
| SCHEMBL1005428 | 0.76 | SCD (0.47) | GPR119FPR2PROKR1 | |
| SCHEMBL1003936 | 0.76 | GPR119 (0.46) | GPR119RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
| EP-2271619-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126535-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR55, NR1H2 | GPR119 1/4885SMN1; SMN2 3819/4885FPR2 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.